Study protocol
One hundred and forty post-renal transplant patients hospitalized at the Third People’s Hospital of Shenzhen for COVID-19 and treated using small-molecule antivirals between December 2022 and January 2023 were included. Patients were divided into azvudine, paxlovid, and azvudine + paxlovid (A+P) groups, according to their treatment status. By comparing the general condition, immunomodulatory treatment, clinical regression, and occurrence of adverse outcomes, such as death, ICU admission, and graft inactivation between the different treatment groups, we provided insights into the management of the novel coronavirus-related pneumonia in patients after kidney transplantation.
This study was strictly conducted per the guidelines of the Declaration of Helsinki of the World Medical Association (2000), and it was approved and supervised by the ethics committee of the Third People’s Hospital of Shenzhen (approval number 2023-036-02).